ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,998.74
-0.38%
Dow Jones
44,722.06
-0.31%
US Dollar vs MXN
20.417
-0.89%
Brent Oil
72.165
-0.32%
Bitcoin
95,611.59
-0.38%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. GlycoMimetics Inc (GLYC)

  7. GlycoMimetics Inc (GLYC) Noticias

GLYC

GlycoMimetics (GLYC)

GlycoMimetics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:GLYC
FechaHoraFuenteTítuloSímboloCompañía
27/11/202413:22Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:GLYCGlycoMimetics Inc
12/11/202407:00PR Newswire (US)Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024NASDAQ:GLYCGlycoMimetics Inc
07/11/202415:47Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:GLYCGlycoMimetics Inc
07/11/202415:42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLYCGlycoMimetics Inc
06/11/202406:00Business WireGlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual MeetingNASDAQ:GLYCGlycoMimetics Inc
04/11/202415:26Edgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:GLYCGlycoMimetics Inc
04/11/202413:01Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:GLYCGlycoMimetics Inc
29/10/202409:00AllPennyStocks.comBiotech Up Over +100% Premarket Following Merger And Funding AnnouncementNASDAQ:GLYCGlycoMimetics Inc
29/10/202409:00AllPennyStocks.comShares of Biotech Company Up Over 100% Premarket Following Merger & Funding AnnouncementNASDAQ:GLYCGlycoMimetics Inc
29/10/202406:00Business WireGlycoMimetics Enters Into Acquisition Agreement With Crescent BiopharmaNASDAQ:GLYCGlycoMimetics Inc
29/10/202405:30Business WireGlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary EndpointNASDAQ:GLYCGlycoMimetics Inc
15/08/202416:01Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:GLYCGlycoMimetics Inc
14/08/202415:13Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:GLYCGlycoMimetics Inc
08/08/202415:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GLYCGlycoMimetics Inc
25/07/202408:00Business WireGlycoMimetics Announces Strategic Review and Corporate Restructuring PlanNASDAQ:GLYCGlycoMimetics Inc
04/06/202406:00Business WireGlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)NASDAQ:GLYCGlycoMimetics Inc
29/05/202415:01Business WireGlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024NASDAQ:GLYCGlycoMimetics Inc
06/05/202405:00Business WireGlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)NASDAQ:GLYCGlycoMimetics Inc
25/04/202406:00Business WireGlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:GLYCGlycoMimetics Inc
27/03/202406:00Business WireGlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023NASDAQ:GLYCGlycoMimetics Inc
13/03/202406:00Business WireGlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024NASDAQ:GLYCGlycoMimetics Inc
26/02/202406:00Business WireGlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care ConferenceNASDAQ:GLYCGlycoMimetics Inc
12/02/202406:00Business WireGlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:GLYCGlycoMimetics Inc
17/01/202415:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLYCGlycoMimetics Inc
04/01/202406:00Business WireGlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687NASDAQ:GLYCGlycoMimetics Inc
03/01/202406:00GlobeNewswire Inc.Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid LeukemiaNASDAQ:GLYCGlycoMimetics Inc
10/12/202311:00Business WireGlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid LeukemiaNASDAQ:GLYCGlycoMimetics Inc
09/11/202306:00Business WireGlycoMimetics to Participate in Upcoming Jefferies London Healthcare ConferenceNASDAQ:GLYCGlycoMimetics Inc
03/11/202306:00Business WireGlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023NASDAQ:GLYCGlycoMimetics Inc
23/10/202307:30PR Newswire (US)Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory BoardNASDAQ:GLYCGlycoMimetics Inc
 Showing the most relevant articles for your search:NASDAQ:GLYC

Su Consulta Reciente

TSX
HFPC.U
Helios Fairfax Partners
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados

BLACK FRIDAY

ADVFN

Celebrando 25 años Est 1999-2024

Ahorra hasta 60%* en Forex

1 año 40%, 2 años 40% y *3 años 60%

*Durante 3 años $1.035.00 solo $414.00